Scarica l'app Stockscreener
3.66
1.61%
-0.06
Pre-mercato:
3.75
0.09
+2.46%
Quantum Biopharma Ltd Borsa (QNTM) Ultime notizie
Nearly 2.9 million people have MS. A drug candidate targeting nerve coating gets FDA trial clearance. - Stock Titan
Quantum BioPharma (QNTM.CN) Receives FDA Clearance for Historic Phase 2 Trial of Lucid-MS in Multiple Sclerosis - kalkine.ca
Quantum BioPharma Ltd.: Financial Data Forecasts Estimates and Expectations | QNTM | CA74764Y2050 - marketscreener.com
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance - The Chronicle-Journal
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Australia
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
Quantum BioPharma Ltd. Receives FDA Clearance To Begin Phase 2 Trial Of Lucid-MS For Multiple Sclerosis - marketscreener.com
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
April press release now tied to Quantum Biopharma (QNTM) securities registration - Stock Titan
March 30 release now part of Quantum Biopharma (QNTM) registration - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
Quantum BioPharma engages FinnCom for investor awareness - scanx.trade
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
QNTM Should I Buy - Intellectia AI
Quantum BioPharma settles CAD$123,487 debt via Class B shares - scanx.trade
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - Quiver Quantitative
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum BioPharma Shares Slip 4.44% as Clinical Risk and Biotech Volatility Temper Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Renewed Pressure as Clinical Execution Risk Tests Investor Confidence - kalkine.ca
Headline: Quantum BioPharma Stock Under Pressure After August 25 Decline — Can Lucid-MS Catalyze a Recovery? - kalkine.ca
Quantum BioPharma Falls 4.26% After FDA Clearance Rally: Profit-Taking or a Deeper Signal? - kalkine.ca
Quantum BioPharma Stock Under Pressure as Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
Quantum (QNTM) Technicals: Trades in a Narrow Directional Range at $3.44 at the Close; the $3.27 to $3.61 Range Remains in Focus in the Latest SessionAdvance Decline Volume - vinanet.vn
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum (QNTM) Chart: Finishes 2.27% Down at $3.44 in the Current Update; Technical View: the Price Remains Bounded by the Supplied Support and Resistance on the DaySentiment Extreme - vinanet.vn
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):